• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

GC Cell

Tuesday, June 04, 2024
Company Presentation Theater 2
GC Cell is at the forefront of the global cell therapy market as a biotech solution pioneer. Our autologous CIK cell product, "Immuncell-LC,"has received approval from the Korean Ministry of Food and Drug Safety (MFDS) as an adjuvant therapy for Hepatocellular Carcinoma. Beyond our approved product, we are actively advancing the development of allogeneic naive NK cell and CAR NK cell products, currently in clinical trials in both the United States and Korea.
GC Cell
Company Website: https://www.gccell.com/en/main.do
Lead Product in Development: Immuncell-LC, CIK therapy (Marketed for adjuvant therapy in HCC) GCC4001, Cord Blood Derived NK Cell Therapy ( Phase 1 & 2 clinical trials for r/r lymphoma)
Number Of Unlicensed Products (For Which You Are Seeking Partners): Immuncell-LC Cord Blood Derived NK (GCC4001) HER2 CAR-NK (GCC2003) CD5 CAR-NK (GCC2005) CD19 CAR-NK (GCC2004)

Exchange

KOSDAQ

Ticker

144510

Company HQ City

Yongin-si

Company HQ State

Gyeonggi-do

Company HQ Country

Korea, Republic of

CEO/Top Company Official

James Park

Development Phase of Primary Product

Multiple Products in Market
Primary Speaker
James Park, MSc
Chief Executive Officer
GC Cell
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS